a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of the safety and efficacy of ABT-089 in adults with attention deficit-hyperactivity disorder (ADHD).
Latest Information Update: 01 Feb 2013
At a glance
- Drugs Pozanicline (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Therapeutic Use
- 18 Aug 2011 Extension trial [NCT00443391] states actual End Date is 1 Oct 2008.
- 18 Aug 2011 Extension trial [NCT00443391] states actual End Date is 1 Oct 2008.
- 18 Aug 2011 Extension trial [NCT00443391] states actual initiation date is 1 Feb 2008.